Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACCP
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Access Pharmaceuticals
accesspharma.com/index.shtml

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

Full Access Pharmaceuticals profile here
Pdf

Access Pharmaceuticals reports healthcare insurance reimbursement progress for MuGard

9th Dec 2010, 2:22 pm
Access Pharmaceuticals reports healthcare insurance reimbursement progress for MuGard

Access Pharmaceuticals (OTCBB: ACCP) said Thursday it is making progress with some major healthcare insurance companies in the US with regards to the recent launch of its lead product, MuGard, a treatment for oral mucositis, a common side effect of cancer therapy.

The company said it has already received MuGard reimbursements from various third-party payer networks. Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harard Pilgrim and Medicaid.

"Receiving these reimbursements affirms that national payers understand the critical role MuGard plays in the management of oral mucositis and serves as strong validation of the clinical and pharmacoeconomic viability MuGard offers," said president and CEO Jeff Davis.

"Our effort to land additional reimbursements is ongoing as it provides an incentive for clinics and hospitals to more quickly integrate the MuGard into their treatment protocols for cancer patients," he added.

Aside from MuGard, Access' products include ProLindac, in phase 2 testing for patients with ovarian cancer, and Thiarabine, in phase 1/2 testing for certain cancers.

The company also has drug delivery technologies including CobaCyte-mediated targeted delivery and CobOral-oral drug delivery, which has led to significant progress in creating oral formulations of insulin for diabetics.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.